Antibodies
SB408124
- 貨號 Cat. No.
- S1545
- 規格 Size
- 5~200mg
- 品牌 Brand
- Selleckchem
Description
SB408124
Catalog No.S1545
SB408124 (Tocris-1963) is a non-peptide antagonist for OX1 receptor with Ki of 57 nM and27 nM in both whole cell and membrane, respectively, exhibits 50-fold selectivity over OX2 receptor.
| Size | Price | Stock | Quantity | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||||||||
Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw
Biological Activity
| Description | SB408124 (Tocris-1963) is a non-peptide antagonist for OX1 receptor with Ki of 57 nM and27 nM in both whole cell and membrane, respectively, exhibits 50-fold selectivity over OX2 receptor. | |||||
|---|---|---|---|---|---|---|
| Targets | OX1 (whole cell) | OX1 (membrane) | ||||
| IC50 | 57 nM (Ki) | 27 nM (Ki) [1] | ||||
| In vitro | SB-408124 binds hypocretin type 1 receptor (HcrtR1) with pKi values of 7.57. Calcium mobilization studies shows that SB-408124 is a functional antagonist of the OX1 receptor with a affinity of approximately 50-fold selectivity over the OX2 receptor. [1] A recent study indicates that pretreatment of primary cultures of rat astrocytes with SB-401824 before Orexin A administration significantly reduced the stimulatory action of Orexin A on both basal and forskolin-acivated cAMP production. [2] | |||||
| In vivo | SB-408124 (30 μg/10 μL, administered intracerebroventricularly) decreases Orexin-A induced water intake in Wistar rats. Intracerebroventricularly administered Orexin-A (30 μg/10 μL) blocks the vasopressin (VP) level increase induced by either histamine or 2.5% NaCl administration, and this blocking effect is moderated by pretreatment with SB-408124. [3] Intracerebroventricular pretreatment with SB-408124 (50 mM, 5 μL/h) prevents Bicuculline (BIC)-induced increases in endogenous glucose production (EGP). [4] | |||||
| Features | ||||||
Protocol(Only for Reference)
Kinase Assay:
| Whole cell binding assays | After overnight culture in 96-well Packard Cultur plates, the medium is discarded and cells are incubated in buffer containing 150 mM NaCl, 20 mM HEPES and 0.5% bovine serum albumin (pH 7.4) for 60 minutes at 25 °C. Saturation studies are carried out by incubating cells with a range of concentrations of [3H]SB-408124 (0.2–24 nM); the total assay volume is 250 μL. Protein content is assayed by lysing cells with 0.1M NaOH and using the Bradford method with bovine serum albumin (BSA) as a standard. Association kinetic studies are performed by measuring the specific binding of [3H]SB-408124 (3 nM) at 1–60 minutes after addition of [3H]SB-408124. All assays are terminated by washing the cells three times with 250μL ice-cold phosphate-buffered saline. A volume of 100 μL of Microscint 40 is added to each well and the plate is left at room temperature for 2 hours. Cell-associated radioactivity is then measured using a Packard Topcount, with a count time of 2 minute/well. |
|---|---|
| Membrane-based SPA binding assays | CHO-K1_OX1 cell membranes (75 μg/mL) are precoupled by shaking with wheatgerm-agglutinin polyvinyltoluene (WGA-PVT) scintillation proximity assay (SPA) beads (5 mg/mL) in buffer containing 25 mM HEPES, 2.5 mM MgCl2, 0.5 mM EDTA and 0.025% bacitracin (pH 7.4) at 4 °C for 1 hour. The bead-membrane suspension is centrifuged at 300× g and resuspended in the same volume of room temperature assay buffer. A volume of 100 μL of bead-membrane suspension is incubated with [3H]SB-674042 (5 nM) in a total assay volume of 200 μL in a 96-well Packard Optiplate to give a final protein concentration of 7.5 μg/well. Nonspecific binding is measured as that remaining in the presence of 3 μM SB-408124. Assay plates are shaken for 10 min and then incubated at room temperature for 4 hours before being counted on a Packard TopCount scintillation counter (count time 2 min/well). Saturation studies are carried out by incubating bead-membranes (equivalent to 7.5 μg protein/well and 2.5 mg beads/mL) with a range of concentrations of [3H]SB-674042 (0.1–20 nM). Protein content is assayed using the Bradford method using bovine serum albumin as a standard. Association kinetic studies are performed by measuring specific binding of [3H]SB-674042 (5 nM) at 1–30 min after addition of bead-membranes (equivalent to 7.5 μg protein/well and 2.5 mg beads/mL). For dissociation studies, bead-membranes are first incubated with [3H]SB-674042 (5 nM) for 30 min. Specific binding is then measured at 2–120 min after the addition of 3 μM SB-408124. Competition studies are performed by incubating bead-membranes (equivalent to 7.5 μg protein/well and 2.5 mg beads/mL) with [3H]SB-674042 (5 nM) and a range of concentrations of the test compound. |
Animal Study:
| Animal Models | Male Wistar rats |
|---|---|
| Dosages | 30 μg/10 μL |
| Administration | Intracerebroventricularly (i.c.v.) injected into the lateral ventricle of the rat. |
| Solubility | 30% propylene glycol, 5% Tween 80, 65% D5W, 30 mg/mL |
References
Chemical Information
| Molecular Weight (MW) | 356.37 |
|---|---|
| Formula | C19H18F2N4O |
| CAS No. | 288150-92-5 |
| Storage | 3 years -20℃Powder |
|---|---|
| 6 months-80℃in DMSO | |
| Syonnyms | N/A |
| Solubility (25°C) * | In vitro | DMSO | 36 mg/mL (101 mM) |
|---|---|---|---|
| Water | <1 mg/mL (<1 mM) | ||
| Ethanol | <1 mg/mL (<1 mM) | ||
| In vivo | 30% propylene glycol, 5% Tween 80, 65% D5W, | 30 mg/mL | |
| * <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. | |||
| Chemical Name | 1-(6,8-difluoro-2-methylquinolin-4-yl)-3-(4-(dimethylamino)phenyl)urea |
|---|
Preparing Stock Solutions
| Stock Solution (1ml DMSO) | 1mM | 10mM | 20mM | 30mM |
|---|---|---|---|---|
| Mass(mg) | 0.35637 | 3.5637 | 7.1274 | 10.6911 |
